`Patent 6,331,415
`
`
`Filed on behalf of: Merck Sharp & Dohme Corp.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________________
`
`MERCK SHARP & DOHME CORP.,
`Petitioner
`
`v.
`
`GENENTECH, INC. AND CITY OF HOPE,
`Patent Owners
`________________________
`
`Case IPR2016-01373
`Patent 6,331,415
`
`________________________
`
`DECLARATION OF KATHERINE A. HELM IN SUPPORT OF
`
`MOTION FOR PRO HAC VICE ADMISSION ON BEHALF OF
`
`PETITIONER MERCK SHARP & DOHME CORP.
`
`Merck Ex. 1075, pg 1605
`
`
`
`Case IPR2016-01373
`Patent 6,331,415
`
`
`I, Katherine A. Helm, declare as follows:
`
`1.
`
`I am an attorney licensed to practice law in the State of New York, the
`
`Commonwealth of Massachusetts, and the District of Columbia. I am also
`
`admitted to practice before the United States Court of Appeals for the Federal
`
`Circuit, the United States Court of Appeals for the Third Circuit, and the United
`
`States District Courts for the Southern and Eastern Districts of New York
`
`2.
`
`I am a senior associate in the law firm of Simpson Thacher & Bartlett
`
`LLP and a member of the Litigation Department and the Intellectual Property
`
`Group in the New York Office. I have approximately eight years of experience as
`
`a patent litigator and trial lawyer, appearing and acting as counsel in numerous
`
`patent litigation matters in various United States District Courts and the United
`
`States Courts of Appeals, including the U.S. Court of Appeals for the Federal
`
`Circuit. The majority of these cases have been within the pharmaceutical and
`
`biotechnology industries. In addition, I spent five years prior to and during law
`
`school working as a technical advisor in the Intellectual Property Group of a large
`
`New York law firm, where I focused on pharmaceutical and biotechnology patent
`
`prosecution and a variety of contested proceedings in the United States Patent and
`
`Trademark Office (“USPTO”) and the European Patent Office.
`
`3.
`
`I am a member in good standing in all jurisdictions and courts where I
`
`have been admitted to practice.
`
`Merck Ex. 1075, pg 1606
`
`
`
`Case IPR2016-01373
`Patent 6,331,415
`
`4.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`5.
`
`I have never had a court or administrative body deny my application
`
`for admission to practice.
`
`6.
`
`I have never been sanctioned or cited for contempt by any court or
`
`administrative body.
`
`7.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in Part 42 of 37 C.F.R.
`
`8.
`
`I agree to be subject to the USPTO Rules of Professional Conduct set
`
`forth in 37 C.F.R. §§ 11.101 et seq. and disciplinary jurisdiction under 37 C.F.R.
`
`§ 11.19(a).
`
`9.
`
`I have not appeared pro hac vice before the Patent Trial and Appeal
`
`Board in the last three years.
`
`10.
`
`I have an established familiarity with the subject matter at issue in this
`
`proceeding, specifically U.S. Patent No. 6,331,415 (“the ’415 patent”). I served as
`
`counsel for Human Genome Sciences Inc. (“HGS”) and Eli Lilly and Company
`
`(“Eli Lilly”) in litigations involving the ’415 patent in Human Genome Sciences
`
`Inc. v. Genentech, Inc. et al., Case No. 2:11-cv-06519 (C.D. Cal.); Human Genome
`
`Sciences Inc. v. Genentech, Inc., Case No. 2:11-cv-06546 (C.D. Cal.); Human
`
`Genome Sciences Inc. v. Genentech, Inc. et al., Case No. 11-082-LPS (D. Del);
`
`
`
`2
`
`Merck Ex. 1075, pg 1607
`
`
`
`Case IPR2016-01373
`Patent 6,331,415
`
`Human Genome Sciences Inc. v. Genentech, Inc., Case No. 11-156-LPS (D. Del.);
`
`and Eli Lilly & Co. et al. v. Genentech, Inc., et al., Case No. 13-cv-07248 (C.D.
`
`Cal).
`
`11.
`
`In addition, I served as counsel for HGS in related district court patent
`
`litigation matters, entitled Human Genome Sciences Inc. v. Genentech, Inc.et al.,
`
`Case No. C.A. No. 11-328-LPS (D. Del); Human Genome Sciences Inc. v.
`
`Genentech, Inc.et al., Case No. 2:11-cv-6594 (C.D. Cal.); Genentech, Inc. et al., v.
`
`Glaxo Group Limited et al., Case No. 2:11-cv-3065 (C.D. Cal.). These litigations
`
`all involved U.S. Patent No. 7,923,221 (“the ’221 patent”), which was filed as a
`
`continuation of the application that issued as the challenged ’415 patent and
`
`involves the same recombinant antibody technology claimed by the ’415 patent.
`
`12.
`
`I also presently serve as counsel for Merck Sharp & Dohme Corp.
`
`(“Merck”) in a patent litigation matter also relating to the ’221 patent, entitled
`
`Merck Sharp & Dohme Corp. v. Genentech, Inc. and City of Hope, Case No. 16-
`
`cv-04992-GW (C.D. Cal.) (“Merck District Court Litigation”). The Merck District
`
`Court Litigation was filed on July 7, 2016.
`
`13. Given my prior involvement in HGS and Eli Lilly cases, and my
`
`current involvement with the Merck District Court Litigation, I have carefully
`
`reviewed, developed an extensive familiarity with, and acquired a substantial
`
`understanding of the ’415 patent and file history, the legal subject matter, the
`
`
`
`3
`
`Merck Ex. 1075, pg 1608
`
`
`
`Case IPR2016-01373
`Patent 6,331,415
`
`factual and technical subject matter, and the prior art and expert testimony
`
`presented in Merck’s request for inter partes review of the ’415 patent, which
`
`forms the basis of this proceeding.
`
`I hereby declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true;
`
`and further that these statements are made with the knowledge that willful false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under Section 1001 of Title 18 of the United States Code and that such willful false
`
`statements may jeopardize the validity of the ’415 patent.
`
`Dated: July 28, 2016
`
`Respectfully submitted,
`
`By: /s/ Katherine A. Helm
` Katherine A. Helm
` SIMPSON THACHER & BARTLETT LLP
` 425 Lexington Avenue
` New York, NY 10017
` Tel: (212) 455-2000
` Fax: (212) 455-2502
`
`
`
`4
`
`
`
`
`
`Merck Ex. 1075, pg 1609